In Figure 2, we report the estimated 1‐year, 3‐year, and 5‐year mortality risk in FTLD patients with varied combinations of predictors: age (− ≤ 64 years; + > 65 years); GS (− = 3 or 4; + = 1 or 2), plasma NfL (− ≤ 65; + > 66), phenotype (− bvFTD or PPA; + FTD‐ALS or PSP or CBS). The gene discussed is NEFL; the disease is supranuclear palsy, progressive, 1.